Understanding the origins of mutations in lung cancer
Cell-of-Origin Footprints of Passenger Mutations in Human Lung Cancer
This study is looking at the different types of normal cells that can turn into lung cancer, hoping to understand how these origins affect the way the cancer grows and how we can treat it better, so that doctors can create more personalized care for patients.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10916571 on NIH RePORTER |
What this research studies
This research investigates the normal cell types from which lung adenocarcinomas arise, aiming to identify how these origins influence cancer development and treatment. By analyzing patterns of passenger mutations in tumors, the study seeks to uncover patient-specific signals that indicate the cell of origin for lung cancer. This approach addresses significant gaps in current knowledge, particularly the variability of cell origins among patients and the limitations of existing models. The findings could lead to improved prognostic tools and therapeutic strategies tailored to individual patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with lung adenocarcinoma who are seeking more effective treatment options.
Not a fit: Patients with other types of lung cancer or those who are not diagnosed with cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment options for lung cancer patients based on the specific origins of their tumors.
How similar studies have performed: While the approach of using passenger mutation patterns to identify cell origins has shown promise in preliminary studies, it has not been rigorously tested in lung cancer, making this research a novel endeavor.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Imielinski, Marcin — New York University School of Medicine
- Study coordinator: Imielinski, Marcin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.